| |
| |
|
| Insider
Information: |
Niven Ralph |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
104,874 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$16,935 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
104,874 |
|
|
| Total
Value |
$16,935 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Windtree Therapeutics Inc |
WINT |
SVP-Preclinical Dev-Fo... |
2005-06-01 |
103,265 |
2004-06-08 |
0 |
Premium* |
|
|
Aerovate Therapeutics, Inc. |
AVTE |
|
2024-02-05 |
1,609 |
2022-08-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
52 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| WINT |
Windtree Therapeutics Inc |
Sr. VP Preclinical Development |
• – – |
2003-12-02 |
4 |
A |
$3.22 |
$4,495 |
D/D |
1,140 |
3,140 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr. VP Preclinical Development |
• – – |
2004-01-23 |
4 |
A |
$8.11 |
$1,501 |
D/D |
185 |
3,325 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr. VP Preclinical Development |
• – – |
2004-04-22 |
4 |
A |
$11.65 |
$1,619 |
D/D |
139 |
3,464 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr VP, Preclinical Development |
• – – |
2004-06-08 |
4 |
OE |
$1.72 |
$25,800 |
D/D |
15,000 |
18,464 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr VP, Preclinical Development |
• – – |
2004-08-02 |
4 |
A |
$9.59 |
$1,630 |
D/D |
170 |
18,634 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr. VP Preclinical Development |
• – – |
2004-10-22 |
4 |
A |
$6.70 |
$1,628 |
D/D |
243 |
18,877 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr. VP Preclinical Development |
• – – |
2004-12-10 |
4 |
S |
$8.28 |
$82,800 |
D/D |
(10,000) |
8,877 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr.VP PreClinical Dev - former |
• – – |
2005-02-15 |
4 |
A |
$7.34 |
$1,621 |
D/D |
221 |
9,098 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr.VP PreClinical Dev - former |
• – – |
2005-05-11 |
4 |
OE |
$1.72 |
$10,750 |
D/D |
6,250 |
15,348 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr.VP PreClinical Dev - former |
• – – |
2005-05-11 |
4 |
S |
$6.40 |
$40,060 |
D/D |
(6,250) |
9,098 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP-Preclinical Dev.-Former |
• – – |
2005-05-18 |
4 |
OE |
$1.72 |
$177,892 |
D/D |
79,167 |
88,265 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP- Preclinical Dev- Former |
• – – |
2005-05-23 |
4 |
S |
$6.65 |
$38,491 |
D/D |
(5,783) |
82,482 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP- Preclinical Dev- Former |
• – – |
2005-05-23 |
4 |
OE |
$3.09 |
$17,869 |
D/D |
5,783 |
88,265 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP- Preclinical Dev-Former |
• – – |
2005-05-24 |
4 |
S |
$6.55 |
$80,607 |
D/D |
(12,217) |
88,265 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP- Preclinical Dev-Former |
• – – |
2005-05-24 |
4 |
OE |
$3.09 |
$37,751 |
D/D |
12,217 |
100,482 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP- Preclinical Dev-Former |
• – – |
2005-05-25 |
4 |
OE |
$4.44 |
$44,400 |
D/D |
10,000 |
98,265 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP- Preclinical Dev-Former |
• – – |
2005-05-25 |
4 |
S |
$6.74 |
$67,777 |
D/D |
(10,000) |
88,265 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP-Preclinical Dev- Former |
• – – |
2005-05-26 |
4 |
OE |
$4.44 |
$67,474 |
D/D |
12,625 |
95,265 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP-Preclinical Dev- Former |
• – – |
2005-05-26 |
4 |
S |
$7.08 |
$89,385 |
D/D |
(12,625) |
88,265 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
SVP-Preclinical Dev-Former |
• – – |
2005-06-01 |
4 |
OE |
$3.09 |
$50,400 |
D/D |
15,000 |
103,265 |
|
- |
|
| AVTE |
Aerovate Therapeutics, In... |
Chief Scientific Officer |
• – – |
2022-08-18 |
4 |
AS |
$21.18 |
$47,657 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
Chief Scientific Officer |
• – – |
2022-08-18 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
Chief Scientific Officer |
• – – |
2022-09-06 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
Chief Scientific Officer |
• – – |
2022-09-06 |
4 |
AS |
$19.00 |
$42,750 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2022-10-05 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
52 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
